- Bladder cancer
Ronac Mamtani, MD, MSCE
Medical Oncology
Accepting new patients
Sees patients age 18 and up
Abramson Cancer Center Perelman 2nd Floor West
Penn Medicine Provider
About me
- Section Chief, Genitourinary Cancers, Hematology-Oncology
- David J. Vaughn MD Associate Professor in GU Oncology
My education and training
- SUNY Stony Brook School of MedicineMedical School
- NewYork-Presbyterian/Weill Cornell Medical CenterResidency
- University of Pennsylvania Health SystemFellowship
Spoken languages
English
English
हिन्दी
Hindi
Reviews
Insurance accepted
Please contact the practice and/or the member services department of your insurance company for specific details before receiving services. Providers may participate in some, but not all, products offered by a health plan; providers may also accept plans at some practice locations but not others.
- Aetna Advantra Cares D-SNP
- Aetna Advantra Credit Value
- Aetna Advantra Eagle HMO
- Aetna Advantra Eagle POS
- Aetna Advantra Premier Plus PPO
- Aetna Advantra Value
- Aetna Advantra Value Plus
- Aetna APCN Plus (Multi-Tier)
- Aetna Better Health Kids (CHIP) - DH Only
- Aetna Flexible Five
- Aetna Freedom Core
- Aetna Gold
- Aetna HMO
- Aetna Philly Prime
- Aetna POS
- Aetna PPO APCN
- Aetna Premier
- Aetna Premier Plus
- Aetna Savings Plus
- Aetna Signature Administrators
- Aetna Student Health Plan PPO
- Aetna Upfront Advantage
- First Health HMO
- First Health POS
- First Health PPO
- Meritain - Aramark (Other)
- Meritain - Aramark (Pennsylvania Premier Medical Plan)
- Americhealth Caritas of PA VIP - LGH Only
- Amerihealth Caritas (Transplant patients only)
- Amerihealth Caritas of PA - LGH Only
- Centivo EPO
- Cigna Healthcare EPO
- Cigna Healthcare HMO
- Cigna Healthcare POS
- Cigna Healthcare PPO
- Claim Watcher (Homestead/ INDECs) Open Access
- Clover Health Choice
- Clover Health Choice Value PPO
- Clover Health Classic HMO
- Clover Health Value
Locations
Penn Medicine hospital privileges
- Hospital of the University of Pennsylvania: Has privileges to treat patients in the hospital.
Dr. Mamtani is a Penn Medicine physician.
Qualifications and experience
- Medical Oncology, 2012
- International Society for Pharmacoepidemiology, International
- National Comprehensive Cancer Network (NCCN) Foundation Young Investigator Award, Grant reviewer; Oncology Clinical Practice Guidelines Committee on Bladder Cancer (Member) 2021-2024, National
- Scientific Advisory Board, Bladder Cancer Advocacy Network, National
- Scientific Program Committee for Health Services Research, American Society of Clinical Oncology; (2023-present) Scientific Program Committee Genitourinary Cancer, American Society of Clinical Oncology, Chair (2023-2024), National
- Scientific Review Committee, The U.K. Health Improvement Network, International
- Urologic cancer care
Treatments and conditions
Research
Publications
Wang X, Long JB, Rothen J, Aremu AO, Huang S, Soulos PR, Robinson TJ, Presley CJ, Goldberg SB, Mamtani R, Wang SY, Ma S, Dinan MA, Gross CP. Matched targeted therapy use after broad genomic profiling in advanced Non-Small cell lung cancer , J Natl Cancer Inst: 2026
Mamtani R, Squires P, Mojebi A, Hale B, Tzontcheva A, Hill-McManus D, Lai Y, Franco S, Frederickson A, Li H. Neoadjuvant, adjuvant, and perioperative therapy comparisons in muscle-invasive bladder cancer: Clinical and methodological considerations for the interpretation of network meta-analytic findings , Urol Oncol: 2026
Mayer M, Seewald NJ, Ulloa-Pérez E, Homet Moreno B, Ramamurthy C, Babcock A, Li H, Mamtani R. Real-World Treatment Duration With First-line Enfortumab Vedotin Plus Pembrolizumab for Advanced Urothelial Cancer: A National Electronic Health Record Study , Clin Genitourin Cancer, 24: 2026,102652
Su L, Chen L, Mamtani R, Betigeri S, Hubbard R, Burcu M. Use of real-world evidence in the U.S. Food and Drug Administration and the European Medicines Agency approvals of oncology products supported by single-arm trials (2022-2025) , Oncologist, 31: 2026,oyag296
Liu H, Merhav D, Tabakovic N, Mamtani R, Khullar K, Christodouleas J. Severe primary organ-related complications in patients with de novo metastatic cancer: implications for prophylactic local therapy , Clin Transl Radiat Oncol, 60: 2026,101238
Squires P, Meng K, Hu X, Turzhitsky V, Kao YH, Stuart J, Ramamurthy C, Li H, Mamtani R. Perioperative Treatment Patterns for Muscle-Invasive Bladder Cancer Patients Undergoing Radical Cystectomy in the Adjuvant Immunotherapy Era: A Retrospective Analysis of US Community Oncology Practice , Oncol Ther: 2026
Mayer M, Seewald N, Babcock A, Homet Moreno B, Ramamurthy C, Li H, Mamtani R. Untreated advanced urothelial carcinoma (aUC) in the modern treatment era: Patterns of care from a decade-long national cohort. , 2026 American Society of Clinical Oncology Annual Meeting, Chicago IL., 44: 2026
Subramanian P, Shyamsunder S, Eshaghi K, Mamtani R, Litt HK. Gaps in patient-facing information on artificial intelligence in cancer care: A cross-sectional analysis. , 2026 American Society of Clinical Oncology Annual Meeting, Chicago IL., 44: 2026
Chow RD, Rothen J, Long JB, Soulos PR, Wang X, Mamtani R, Ma S, Kunst N, Dinan MA, Gross CP. Medicare Insurance Type and Broad Genomic Profiling in Metastatic Cancer , JAMA Netw Open, 9: 2026,e2614919
Martei YM, Chen K, Obasohan M, Mamtani R, Aakhus E, Shulman LN, Hubbard RA, Clark A. Racial disparities and utilization trends of first-line targeted therapies for metastatic breast cancer , JNCI Cancer Spectr, 10(3): 2026,pkag043